GB9929973D0 - Heterocyclic compounds - Google Patents
Heterocyclic compoundsInfo
- Publication number
- GB9929973D0 GB9929973D0 GBGB9929973.7A GB9929973A GB9929973D0 GB 9929973 D0 GB9929973 D0 GB 9929973D0 GB 9929973 A GB9929973 A GB 9929973A GB 9929973 D0 GB9929973 D0 GB 9929973D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9900518 | 1999-01-11 | ||
GBGB9915510.3A GB9915510D0 (en) | 1999-07-03 | 1999-07-03 | Heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
GB9929973D0 true GB9929973D0 (en) | 2000-02-09 |
GB2345486A GB2345486A (en) | 2000-07-12 |
Family
ID=26314972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB9929973A Withdrawn GB2345486A (en) | 1999-01-11 | 1999-12-17 | Heteroaromatic protein tyrosine kinase inhibitors |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2345486A (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ306810B6 (en) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | The use of a quinazoline derivative as an inhibitor of angiogenesis |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US7371765B2 (en) * | 2000-08-09 | 2008-05-13 | Astrazeneca Ab | Quinoline derivatives having VEGF inhibiting activity |
US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
NZ516873A (en) * | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
AR035791A1 (en) * | 2001-03-23 | 2004-07-14 | Bayer Corp | COMPOUND N, N-DIHETEROCICLICO OF AMINA, INHIBITOR OF THE RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE COMPOUND |
AU2002245709A1 (en) * | 2001-03-23 | 2002-10-08 | Bayer Corporation | Rho-kinase inhibitors |
ES2263743T3 (en) | 2001-04-13 | 2006-12-16 | Pfizer Products Inc. | DERIVATIVES OF 4-AMINOPIRIDOPIRIMIDINE REPLACED WITH A BICYCLE GROUP. |
KR100810468B1 (en) * | 2001-10-10 | 2008-03-07 | 씨제이제일제당 (주) | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor |
US7268230B2 (en) | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
EP1487436A4 (en) | 2002-03-08 | 2009-06-03 | Signal Pharm Inc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
WO2004046101A2 (en) | 2002-11-20 | 2004-06-03 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
JP2006515846A (en) * | 2002-12-13 | 2006-06-08 | ニューロジェン・コーポレーション | 2-Substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
TW200510373A (en) * | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US20080085901A1 (en) * | 2005-01-14 | 2008-04-10 | Neurogen Corporation | Heteroaryl Substituted Quinolin-4-Ylamine Analogues |
WO2009012647A1 (en) * | 2007-07-20 | 2009-01-29 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Preparation methods of quinazoline derivatives and their pharmaceutical uses |
CN102108079B (en) * | 2009-12-25 | 2014-10-01 | 齐鲁制药有限公司 | 4-anilino quinazoline derivatives serving as tyrosine kinase inhibitors |
CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
US9499530B2 (en) * | 2011-08-01 | 2016-11-22 | Hangzhou Minsheng Institutes For Pharma Research | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament |
TWI547494B (en) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | Amino quinazolines as kinase inhibitors |
TW201425307A (en) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
TWI592417B (en) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | Prodrugs of amino quinazoline kinase inhibitor |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (en) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Therapeutic compounds and their uses |
WO2014128622A1 (en) | 2013-02-21 | 2014-08-28 | Glaxosmithkline Intellectual Property Development Limited | Quinazolines as kinase inhibitors |
CN103772411B (en) * | 2013-04-28 | 2016-08-03 | 复旦大学 | Sulfur-bearing 6-furyl quinazoline-4-amines and its production and use |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP6426194B2 (en) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | Crystalline forms of therapeutic compounds and uses thereof |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
-
1999
- 1999-12-17 GB GB9929973A patent/GB2345486A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2345486A (en) | 2000-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9929973D0 (en) | Heterocyclic compounds | |
GB9800575D0 (en) | Heterocyclic compounds | |
HUP0203375A3 (en) | Substituted oxoazaheterocyclyl compounds | |
GB2357761B (en) | Compounds | |
GB9904933D0 (en) | Compounds | |
AU5884101A (en) | Heterocyclic compounds | |
AP2002002413A0 (en) | Heterocyclic compounds inhibiting angiogenesi | |
GB9902399D0 (en) | Compounds | |
GB9904930D0 (en) | Thiazoloindolinone compounds | |
IL150010A0 (en) | Heterocyclic derivatives | |
GB9916218D0 (en) | Heterocyclic compounds | |
GB9916216D0 (en) | Heterocyclic compounds | |
GB9915510D0 (en) | Heterocyclic compounds | |
GB9916213D0 (en) | Heterocyclic compounds | |
GB9914173D0 (en) | New heterocyclic compounds | |
GB9800571D0 (en) | Heterocyclic compounds | |
GB9800567D0 (en) | Heterocyclic compounds | |
GB9812408D0 (en) | Heterocyclic compounds | |
GB9800572D0 (en) | Heterocyclic compounds | |
GB9812403D0 (en) | Heterocyclic compounds | |
GB9800564D0 (en) | Heterocyclic compounds | |
GB9800557D0 (en) | Heterocyclic compounds | |
GB9903337D0 (en) | Heterocyclic derivatives | |
GB9929038D0 (en) | Heterocyclic derivatives | |
GB9903241D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) | ||
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |